Implementation of a Managed Access program can be a step into the unknown.

Even with all the best-laid plans, pharmaceutical and biotech companies can’t be sure where demand will come from, for which patients’ access will be requested, and how large the program will be.

Chances are the first request may be for a patient outside the original scope, that demand will be different to what was originally forecasted, and that the program scope will need to adjust alongside the global commercial roll-out.

Pharmaceutical and biotech companies need a partner that can do more than just execute the plan. They need a partner with the capability, experience and resources that can adapt to ensure no eligible patient goes without treatment.

With more than 35 years’ experience across 350+ programs, Clinigen help pharmaceutical and biotech companies navigate this ever-changing global environment.

With the industry’s largest team focused on early access and expertise in regularly supplying 100+ countries, Clinigen will ensure the delivery of a program that means the right medicine gets to the right patient at the right time.

Getting early access right is critical, and that’s why pharmaceutical and biotech companies trust Clinigen.